Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, announced that it has partnered with Triumph Research Intelligence (TRI), a global company focused in centralized and risk-based quality management (RBQM) technology.
“We’re very excited about this collaboration with TRI, as it will enable us to deliver an even better service to our Sponsors,” said Matthew Healy, Vice President, Clinical Operations at Rho. “Having a fully validated tool that delivers the entire end-to-end RBQM processes is a key differentiator for us. It means that we can be confident in identifying and documenting potential study risks right from the start, then using the tools we can spot and manage emerging trends, acting much more quickly to target our onsite monitoring activities and focus our efforts on those areas that will improve data quality and better ensure patient safety.”
TRI’s RBQM technology platform optimizes trial quality by improving data reliability, patient safety and operational efficiency. Regulatory guidance requiring the adoption of RBQM has led to a rapid increase in demand for centralized and risk-based monitoring solutions from CROs and Sponsors.
“We’re delighted to be partnering with Rho as they are one of the leading CRO’s with a global reputation for excellence,” said Duncan Hall, CEO and Founder of TRI. “In a world of big data, it’s still people that have to make the decisions. Our RBQM technology platform, OPRA, will enable Rho and their Sponsors to make better informed decisions faster, leading to better quality trials and improved patient safety.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.